# Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects

> **NCT02182323** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 74 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 201335 NA
- **DRUG:** Placebo solution

## Key facts

- **NCT ID:** NCT02182323
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2006-12
- **Final completion:** —
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2014-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02182323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02182323, "Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02182323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*